Document is current
Any future updates will be listed below
-
Authors
Jayavelu, Ashok Kumar
Schnöder, Tina M.
Perner, Florian
Herzog, Carolin
Meiler, Arno https://orcid.org/0000-0003-0012-7952
Krishnamoorthy, Gurumoorthy https://orcid.org/0000-0002-7798-6707
Huber, Nicolas
Mohr, Juliane
Edelmann-Stephan, Bärbel
Austin, Rebecca
Brandt, Sabine
Palandri, Francesca https://orcid.org/0000-0001-8367-5668
Schröder, Nicolas
Isermann, Berend
Edlich, Frank
Sinha, Amit U.
Ungelenk, Martin
Hübner, Christian A.
Zeiser, Robert https://orcid.org/0000-0001-6565-3393
Rahmig, Susann
Waskow, Claudia https://orcid.org/0000-0003-3261-0922
Coldham, Iain https://orcid.org/0000-0003-4602-6292
Ernst, Thomas
Hochhaus, Andreas
Jilg, Stefanie
Jost, Philipp J. https://orcid.org/0000-0003-2454-0362
Mullally, Ann
Bullinger, Lars
Mertens, Peter R.
Lane, Steven W. https://orcid.org/0000-0002-8050-6209
Mann, Matthias https://orcid.org/0000-0003-1292-4799
Heidel, Florian H. https://orcid.org/0000-0003-2438-1955
- License Information
-
More Information
Article History
Received: 11 December 2018
Accepted: 15 September 2020
First Online: 25 November 2020
Competing interests
: F.H.H. has served as an advisory board member for and received research funding from Novartis, Celgene and CTI. S.W.L. has served on an advisory board for Novartis Australia. A.H. received research support by Novartis, BMS, Pfizer, Incyte. A.M. has received honoraria from Blueprint Medicines, Roche and Incyte and receives research support from Janssen and Actuate Therapeutics. No potential conflicts of interest were disclosed by the other authors.
